Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild‐to‐moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost‐effective for community‐dwelling, moderate‐to‐severe Alzheimer's disease patients. Methods: Cost‐effectiveness analysis was based on a 52‐week, multicentre, double‐blind, placebo‐controlled, factorial clinical trial. A total of 295 community‐dwelling patients with moderate/severe Alzheimer's disease, already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii) discontinue donepezil and start memantine; or (iv) continue donepezil and start memantine. Results: Continuing donepezil for 52 weeks was more cost‐effective than discontinuation, considering cognition, activities of daily living and health‐related quality of life. Starting memantine was more cost‐effective than donepezil discontinuation. Donepezil–memantine combined is not more cost‐effective than donepezil alone. Conclusions: Robust evidence is now available to inform clinical decisions and commissioning strategies so as to improve patients' lives whilst making efficient use of available resources. Clinical guidelines for treating moderate/severe Alzheimer's disease, such as those issued by NICE in England and Wales, should be revisited. © 2016 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657 · cited 3×
“, 2007) (range 31–134, higher scores indicate better quality of life) rated by carers; • generic health-related quality of life: EQ-5D-3L (EuroQol Group, 1990) rated by carers; • health status of family or other unpaid carers: General Health Questionnaire (GHQ-12) (Goldberg et al., 1997) (range 0–12, higher scores ind…”
BackgroundMcShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Self-citationDonepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272 · cited 1×
“There is evidence that memantine is effective and cost-saving in moderate and severe AD (Areosa et al., 2005; Wimo et al., 2003), but it is not clear whether memantine in combination with an AChE inhibitor confers additional clinical benefits (Tariot et al., 2004; Porsteinsson et al., 2008).”
BackgroundDetermining the minimum clinically important differences for outcomes in the DOMINO trial
Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C., et al. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2607 · Cited by 185
Self-citationSurveillance for ocular hypertension: an evidence synthesis and economic evaluation.
Burr, J., Botello-Pinzon, P., Takwoingi, Y., Hernández, R., Vazquez-Montes, M., Elders, A., Asaoka, R., Banister, K., van der Schoot, J., Fraser, C., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16290 · Cited by 180
Dementia care costs and outcomes: a systematic review
Knapp, M., Iemmi, V., & Romeo, R. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3864 · Cited by 126
Self-citation
Cited by
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Economics and mental health: the current scenario
Knapp, M., & Wong, G. (2020) · World Psychiatry · doi:10.1002/wps.20692 · Cited by 409
Self-citationCognitive symptoms of Alzheimer’s disease: clinical management and prevention
Joe, E., & Ringman, J. M. (2019) · BMJ · doi:10.1136/bmj.l6217 · Cited by 321
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Self-citationTherapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Metadata
- Authors
- Knapp, M., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., Burns, A., Dening, T., Findlay, D., Holmes, C., Johnson, T., Jones, R., Katona, C., Lindesay, J., Macharouthu, A., McKeith, I., McShane, R., O'Brien, J. T., Phillips, P. P. J., Sheehan, B., & Howard, R.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2016-10-13
- Volume
- 32
- Issue
- 12
- Pages
- 1205-1216
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2513465760
- Cited by
- 63
- References
- 7
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.